HomeARWR • NASDAQ
Arrowhead Pharmaceuticals Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 27.77M | — |
Operating expense | 193.32M | 9.75% |
Net income | -175.24M | -2.60% |
Net profit margin | -631.11 | — |
Earnings per share | -1.26 | 8.70% |
EBITDA | -159.33M | 7.02% |
Effective tax rate | 0.24% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 898.17M | 106.73% |
Total assets | 1.38B | 56.22% |
Total liabilities | 860.81M | 58.01% |
Total equity | 519.81M | — |
Shares outstanding | 138.26M | — |
Price to book | 4.97 | — |
Return on assets | -28.02% | — |
Return on capital | -31.14% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -175.24M | -2.60% |
Cash from operations | -154.72M | -34.05% |
Cash from investing | 141.39M | 1,934.68% |
Cash from financing | -42.68M | -184.70% |
Net change in cash | -55.92M | 4.10% |
Free cash flow | -111.88M | -59.90% |
Previous close
$18.78
Day range
$18.73 - $20.58
Year range
$9.57 - $27.33
Market cap
2.84B USD
Avg Volume
2.14M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
609
